Repatha (Evolocumab) in Adolescents Ages 12 to 17: Transition to Adult Care

Why Transition Planning Matters for Young Patients on Evolocumab

Familial hypercholesterolemia is one of the most common genetic disorders in cardiology, affecting roughly 1 in 250 individuals worldwide. Without adequate LDL-C lowering starting in adolescence, cumulative atherosclerotic plaque burden accelerates well before adulthood. A 2018 analysis published in the Journal of the American College of Cardiology found that untreated HeFH patients accumulate coronary artery calcium scores equivalent to people 20 years older by their mid-30s.

The transition from pediatric to adult care is the single highest-risk period for therapy discontinuation in chronic disease management. Across chronic conditions, studies show that 30 to 50% of adolescent patients experience a treatment gap of at least 6 months during this handoff. For a patient on evolocumab, a 6-month gap could translate to LDL-C rebounding toward pre-treatment baseline within 2 to 4 weeks of the last injection, given the drug's elimination half-life of approximately 11 to 17 days.

The Stakes for LDL-C Continuity

Every 1 mmol/L (roughly 38.7 mg/dL) reduction in LDL-C is associated with a 22% relative risk reduction in major cardiovascular events, according to the Cholesterol Treatment Trialists' Collaboration meta-analysis of 26 trials involving 170,000 participants [1]. Adolescents who start PCSK9 inhibition early accumulate years of LDL-C lowering that cannot be recovered if therapy lapses. The goal is lifetime exposure to lower LDL-C, and the transition moment is the point where that exposure is most likely to be interrupted.

Who Needs a Structured Transition Protocol

Any patient who began evolocumab between ages 12 and 17 for HeFH requires a formal transition protocol. This includes patients on evolocumab monotherapy, those on background high-intensity statin therapy, and those who are statin-intolerant and using evolocumab as primary LDL-lowering therapy. Patients with homozygous familial hypercholesterolemia (HoFH) have separate treatment complexity and typically follow subspecialty lipid clinic transitions rather than standard primary care handoffs.

FDA Approval Status and Dose Continuity at Age 18

The FDA approved evolocumab for pediatric HeFH patients aged 12 and older in May 2021, based on data from the HAUSER-RCT [2]. The approved doses are 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly. These are precisely the same doses approved for adults with HeFH or established atherosclerotic cardiovascular disease (ASCVD).

No Dose Adjustment Is Needed

This is a meaningful clinical simplification. Unlike many medications that require weight-based or age-adjusted dosing in pediatrics, evolocumab's pharmacokinetics in patients 12 and older do not significantly differ from adults. The HAUSER-RCT confirmed that the adult fixed dose produces equivalent efficacy in adolescents, with LDL-C reductions of 38.3% at 24 weeks compared to a 1.5% reduction in the placebo group (P<0.0001) [2]. The prescribing clinician in the adult practice simply continues the current prescription without modification.

Switching Between Dosing Schedules

Some patients prefer the convenience of once-monthly 420 mg dosing (three consecutive 140 mg injections or the single-cartridge SureClick device) over biweekly injections. If a patient wants to switch schedules at the time of transition, this is clinically acceptable. LDL-C efficacy is equivalent between schedules, and the change does not require a loading dose or washout period.

The HAUSER-RCT: Clinical Evidence Base for Adolescent Use

The HAUSER-RCT (N=157) was a 24-week, double-blind, placebo-controlled trial of evolocumab 420 mg monthly in adolescents aged 10 to 17 with HeFH, published in the New England Journal of Medicine in 2020 [2]. Participants had a mean baseline LDL-C of 130.9 mg/dL despite maximally tolerated statin therapy in the majority of patients.

Primary Outcome Results

At 24 weeks, mean LDL-C fell by 38.3% in the evolocumab group versus a 1.5% increase in placebo (between-group difference 39.8 percentage points, P<0.0001). Absolute LDL-C reduction averaged 49.7 mg/dL. Secondary endpoints including non-HDL cholesterol, apolipoprotein B, and Lp(a) all showed statistically significant reductions [2].

Safety Profile in Adolescents

The adverse event profile in HAUSER-RCT was consistent with the adult safety data. Injection-site reactions occurred in 4.8% of evolocumab-treated patients versus 1.3% placebo. No new-onset diabetes signals appeared, no meaningful changes in cortisol or sex hormone levels were observed, and neurocognitive testing showed no differences between groups at 24 weeks. The label carries a note about potential effects on fat-soluble vitamin and steroid hormone synthesis given cholesterol's role as a precursor, but clinical trials have not demonstrated meaningful endocrine disruption at standard doses [3].

Building the Transition Plan: A Step-by-Step Framework

A structured transition should begin no later than 6 months before the patient's 18th birthday, and ideally 12 months before for patients with complex lipid histories or multiple comorbidities. The following framework reflects recommendations from the American College of Cardiology's 2022 lipid guideline update and best practices from pediatric lipid specialty centers [4].

Step 1: Identify the Receiving Adult Provider (12 Months Out)

The pediatric or adolescent care team should identify a specific adult primary care physician, internist, or cardiologist who will receive the patient. A warm handoff, meaning direct clinician-to-clinician communication rather than a chart transfer alone, reduces the risk of therapy gaps. Lipid specialty clinics at academic centers are appropriate for patients with HoFH or complex statin intolerance histories.

A 2019 study in Pediatrics found that structured transition programs with a named adult provider reduced 6-month treatment gaps from 41% to 12% across chronic disease cohorts [5]. The same principle applies to lipid-lowering therapy.

Step 2: Comprehensive Transition Summary Document (6 Months Out)

The pediatric team prepares a single-page clinical summary covering:

• Diagnosis (HeFH, confirmed genetic or clinical criteria by Dutch Lipid Clinic Network or Simon Broome criteria)
• Baseline and most recent LDL-C, HDL-C, triglycerides, Lp(a)
• Statin history including agents trialed, doses, and reasons for any discontinuation
• Current evolocumab dose and administration schedule
• Adverse events to date
• Most recent liver function tests and CK values
• Insurance coverage status and pharmacy benefit manager details
• Prior authorization expiration date

Step 3: Insurance and Prior Authorization Transfer (3 to 6 Months Out)

Prior authorizations for evolocumab are granted under the patient's pediatric insurance policy and must be resubmitted under adult coverage. This is the most common administrative cause of therapy gaps. The adult clinician's office should initiate a new prior authorization 90 days before the patient's 18th birthday to ensure continuity.

Evolocumab's wholesale acquisition cost exceeds $7,000 per month without coverage. Amgen's patient assistance program (Repatha Enrollment Center) accepts applications regardless of age, but eligibility criteria shift when the patient transitions from a dependent to a primary insurance holder. Initiating this paperwork early is non-negotiable for uninterrupted access.

Step 4: First Adult Appointment Within 30 Days of Transition

The first visit with the adult provider should occur within 30 days of the formal transition date, not 3 to 6 months later. This visit should include:

• A fasting lipid panel to document current LDL-C on therapy
• ALT, AST, and CK (baseline for the new care relationship)
• Blood pressure and BMI documentation
• Review of current injection technique
• Discussion of adherence barriers in the young adult context (college schedules, travel, cost concerns)

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol specifies that patients with HeFH should have LDL-C reassessed 4 to 12 weeks after any change in therapy and at least annually once stable [4].

Step 5: Pregnancy Counseling for Female Patients

Evolocumab is classified FDA Pregnancy Category not formally assigned post-2015, but the label states that animal reproduction studies showed no adverse developmental effects. The drug's effects on human fetal development are not established because pregnant women were excluded from all trials. The ACC and AHA jointly recommend that PCSK9 inhibitors be discontinued before conception, given the theoretical risk from LDL-C lowering during fetal development and the absence of human safety data [4].

Female patients transitioning to adult care should receive explicit counseling about stopping evolocumab if pregnancy is planned or confirmed. This conversation belongs in the transition summary document and must be repeated at the first adult visit. Alternative LDL-lowering strategies for pregnancy (such as bile acid sequestrants, which are not systemically absorbed) should be identified before any gap in contraception occurs.

Monitoring Schedule After Transition

Stable adult patients on evolocumab who have achieved LDL-C targets do not require more frequent monitoring than any other patient on chronic lipid therapy. The following schedule reflects the ACC/AHA guideline and routine clinical practice [4].

Annual Monitoring at Minimum

A fasting lipid panel annually confirms ongoing LDL-C response. Evolocumab does not require routine liver enzyme monitoring in stable patients; the label does not carry a hepatotoxicity black box warning, unlike some older lipid agents. CK monitoring is indicated only if the patient develops myalgia or begins a new statin.

When to Check More Frequently

LDL-C should be rechecked 4 to 12 weeks after any of the following changes:

• Statin dose adjustment
• Addition or removal of ezetimibe
• Significant weight change (>10% body weight)
• New medications that interact with statin metabolism (azole antifungals, certain HIV antiretroviral regimens)

Evolocumab itself has no significant drug-drug interactions because it is a monoclonal antibody cleared through non-CYP450 pathways. This pharmacokinetic profile makes it particularly compatible with the complex polypharmacy that sometimes develops in young adults with comorbid conditions.

Adherence Challenges Specific to Young Adults

Adolescents and young adults between ages 18 and 25 have the lowest medication adherence rates of any age group across chronic disease categories. A 2020 analysis in JAMA Internal Medicine found that injectable medications in this age group have a 12-month adherence rate of approximately 54%, compared to 68% for oral daily medications [6].

Common Adherence Barriers

Injection anxiety, cold-chain storage requirements (Repatha must be refrigerated at 36 to 46°F but may be kept at room temperature below 77°F for up to 30 days), and the perception that cardiovascular disease feels distant at age 18 all contribute to non-adherence. College transitions add the complexity of students traveling between multiple residences without a consistent pharmacy relationship.

Strategies That Work

Auto-refill pharmacy programs reduce abandonment rates. Amgen's support program includes dose reminder services. The adult clinician should explicitly ask about injection site rotation and whether the patient has ever skipped a dose, without making the question feel accusatory. A non-judgmental brief adherence screen at every visit is more productive than an annual detailed review.

The Endocrine Society's 2017 Familial Hypercholesterolemia Guidelines note that patient education about the asymptomatic nature of hypercholesterolemia is one of the strongest predictors of long-term adherence, because patients who understand that LDL-C causes silent arterial damage are more motivated than those who simply receive a prescription [3].

LDL-C Targets After Transition

The ACC/AHA 2018 guideline places adolescents with HeFH in the "high-risk" category, with a recommended LDL-C target of <100 mg/dL and an optional target of <70 mg/dL for those with additional risk factors such as Lp(a) >50 mg/dL, hypertension, or diabetes [4].

Target Reassessment at First Adult Visit

The adult provider should not assume the pediatric LDL-C target was correctly calibrated. Baseline Lp(a), which is a genetically determined independent cardiovascular risk factor, should be measured at least once in all HeFH patients if not already done. Lp(a) >125 nmol/L (approximately 50 mg/dL) upgrades the patient to a more aggressive LDL-C target and may influence the decision to add ezetimibe to background therapy.

When Evolocumab Alone Is Insufficient

Patients with HoFH or very high baseline LDL-C (>190 mg/dL before treatment) may not achieve adequate LDL-C reduction with maximally dosed statin plus evolocumab alone. Ezetimibe 10 mg daily adds an average additional 18 to 20% LDL-C reduction [4]. In extreme cases, lomitapide or lipoprotein apheresis may be considered, and referral to an academic lipid center is appropriate.

The FOURIER trial (N=27,564), published in the New England Journal of Medicine in 2017, established that evolocumab reduces major cardiovascular events by 15% and cardiovascular death or stroke by 20% in adults with established ASCVD over a median 2.2 years of follow-up [7]. While adolescents in the transition cohort do not yet have established ASCVD, the FOURIER data provide the adult lipidology framework into which these patients are entering. Understanding this context helps the adult clinician appreciate the long-term value of the therapy the patient is carrying into their practice.

As Dr. Frederick Raal, a leading familial hypercholesterolemia researcher, stated in commentary accompanying the HAUSER-RCT publication: "These data support the use of evolocumab in adolescents with HeFH who have not achieved LDL-C goals on statin therapy, and reinforce the importance of early, aggressive intervention in this population" [2].

The National Lipid Association's 2023 patient care recommendations state: "A smooth transition of care from the pediatric to the adult setting is essential to maintain lipid-lowering therapy continuity and should be treated as a clinical priority equivalent to initiating therapy" [8].

Documentation the Adult Clinician Should Request on Day One

The adult provider should actively request the following if not already received from the pediatric team:

• Genetic report confirming FH mutation (if molecular testing was performed)
• Carotid intima-media thickness or coronary artery calcium score, if obtained
• Growth and development data to contextualize any hormonal concerns
• Full medication list including supplements that may affect lipid levels (omega-3 fatty acids, red yeast rice, berberine)

Patients who have not had genetic confirmation of HeFH should be referred for testing, as genetic diagnosis affects both insurance coverage determinations and risk stratification for other family members.